Lawless Michael A bought $9,940 worth of Ordinary Shares (2,000 units at $4.97), increasing direct ownership by 93% to 4,150 units (SEC Form 4)

$LFWD
Industrial Specialties
Health Care
Get the next $LFWD alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lawless Michael A

(Last) (First) (Middle)
C/O REWALK ROBOTICS LTD.
3 HATNUFA ST., P.O. BOX 161

(Street)
YOKNEAM ILIT L3 20692203

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ReWalk Robotics Ltd. [ LFWD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
05/23/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares, par value NIS 1.75 per share 05/23/2024 P 2,000(1) A $4.9702 4,150(2) D
Ordinary Shares, par value NIS 1.75 per share 55,713(2) I ESOP
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents Ordinary Shares purchased in the open market on May 23, 2024.
2. The reported number of shares has been adjusted to reflect the impact of the Issuer's 1-for-7 reverse share split, which became effective on March 15, 2024.
/s/ Michael Lawless 05/28/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $LFWD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LFWD

DatePrice TargetRatingAnalyst
2/10/2025$10.00Buy
Laidlaw
More analyst ratings

$LFWD
Press Releases

Fastest customizable press release news feed in the world

See more
  • FDA Issues Clearance for ReWalk 7 Exoskeleton

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that the Company has received 510(k) FDA clearance for the newest generation of its personal exoskeleton device, the ReWalk 7. The seventh generation of the ReWalk, a wearable exoskeleton that allows individuals with spinal cord injury (SCI) to stand and walk again, includes a number of new features, as well as enhancements and upgrades. "FDA clearance is a major milestone for our Company and for the industry,"

    $LFWD
    Industrial Specialties
    Health Care
  • Lifeward Ltd. Reports Fourth Quarter and Full Year 2024 Financial Results

    Record quarterly and annual revenue of $7.5M and $25.7M, respectively Continued strong growth in U.S. pipeline of ReWalk opportunities with over 110 qualified leads in process Strategic shift towards profitability: 2025 Sustainable Growth Plan focuses on growth of core product lines with a streamlined cost structure and reduced operating loss MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months and full year ended Decem

    $LFWD
    Industrial Specialties
    Health Care
  • Lifeward and CorLife Finalize Partnership to Expand Workers' Compensation Access to ReWalk Exoskeleton

    CorLife to become the exclusive distributor of the ReWalk Personal Exoskeleton for individuals with Workers' Compensation claims Partnership expected to enable Lifeward to achieve greater growth and penetration into the Workers' Compensation market MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel and GREEN BAY, Wis., March 06, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward") a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, and CorLife, LLC., ("CorLife") a division of Numotion, the nation's leading and largest provider of products and services that provide mobility

    $LFWD
    Industrial Specialties
    Health Care

$LFWD
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$LFWD
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$LFWD
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$LFWD
SEC Filings

See more

$LFWD
Leadership Updates

Live Leadership Updates

See more
  • Lifeward Announces Appointment of Robert J. Marshall to Its Board of Directors

    MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions in physical rehabilitation and recovery, announced the Board of Directors has approved the appointment of Robert J. Marshall Jr. as a new director effective November 2, 2024. As part of his duties as a director, Mr. Marshall will serve as Chairman of the Audit Committee. Mr. Marshall has had a long and accomplished finance career in the medical device industry. Currently, Mr. Marshall serves as the Chief Financial Officer and Treasurer of Lantheus Holdings, Inc., a publicly traded radiopharmaceut

    $LFWD
    Industrial Specialties
    Health Care
  • Lifeward Announces Appointment of Dr. Keith E. Tansey as Consulting Director of Clinical Research

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™) (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that Dr. Keith E. Tansey, MD, PhD, will be joining its Medical Affairs team as a consultant in the role of Director, Clinical Research. Dr. Tansey's responsibilities will include the development and stewardship of Lifeward's clinical research program, the advancement of key opinion leader opportunities, and iden

    $LFWD
    Industrial Specialties
    Health Care
  • Lifeward Announces Appointment of Joseph E. Turk as Incoming Chairman of its Board of Directors

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, July 02, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™) (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that Jeff Dykan, current Chairman of the Lifeward Board of Directors, will retire from his role and will not stand for reelection effective at the 2024 Annual Meeting of Shareholders. Joseph Turk, who has served on Lifeward's Board since 2022, has been appointed as the incoming Chairman and will assume the role f

    $LFWD
    Industrial Specialties
    Health Care

$LFWD
Financials

Live finance-specific insights

See more
  • Lifeward to Report Fourth Quarter and Fiscal Year-End 2024 Financial Results on March 7, 2025

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a  global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its fourth quarter and fiscal year-end financial results before the markets open on Friday, March 7, 2025. Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-3

    $LFWD
    Industrial Specialties
    Health Care
  • Lifeward Announces CEO Transition

    CEO Larry Jasinski to Retire Company Begins Search for New Leader to Drive Next Phase of Growth Company Provides Preliminary Full-Year 2024 Revenue Reschedules Virtual Investor Event Until Later in 2025 After Hiring of New CEO MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Larry Jasinski, the Company's Chief Executive Officer, will step down after a distinguished 13-year career at the Company. Mr. Jasinski will continue to serve in his existin

    $LFWD
    Industrial Specialties
    Health Care
  • Lifeward Ltd. Reports Third Quarter 2024 Financial Results

    Second consecutive quarter of 20 ReWalk systems sold Robust growth in U.S. ReWalk pipeline of approximately 70 qualified leads for potential claim submission with Medicare and other U.S. payors MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions in physical rehabilitation and recovery, today announced its financial results for the three months and nine months ended September 30, 2024. Recent Highlights and Milestones for Lifeward Lifeward initiated actions to further streamline its U.S. operations including closing two U.S. facili

    $LFWD
    Industrial Specialties
    Health Care